Published in Obesity (Silver Spring) on April 28, 2017
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov (2008) 4.43
Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev (2002) 4.41
Bile acids: regulation of synthesis. J Lipid Res (2009) 4.31
A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology (2007) 3.65
A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol (2010) 3.53
Amino acids: metabolism, functions, and nutrition. Amino Acids (2009) 2.92
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (2016) 2.63
Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol (2008) 2.33
Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol (2010) 2.32
Bile-acid-induced cell injury and protection. World J Gastroenterol (2009) 2.06
Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism (2010) 1.77
Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos (2009) 1.67
Essential pathogenic and metabolic differences in steatosis induced by choline or methione-choline deficient diets in a rat model. J Gastroenterol Hepatol (2007) 1.67
Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. J Hepatol (2003) 1.35
Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos (2011) 1.33
New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med (2009) 1.32
Mitochondrially-mediated toxicity of bile acids. Toxicology (2004) 1.26
Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol (2014) 1.25
Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab Dispos (2011) 1.24
Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol (2012) 1.17
Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur J Pharmacol (2009) 1.16
Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method. J Lipid Res (2012) 1.10
Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicol Appl Pharmacol (2013) 1.08
Oxidation of hepatic carnitine palmitoyl transferase-I (CPT-I) impairs fatty acid beta-oxidation in rats fed a methionine-choline deficient diet. PLoS One (2011) 1.04
Rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Int J Mol Sci (2013) 1.04
Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models. Drug Metab Dispos (2014) 1.04
Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease. Am J Physiol Regul Integr Comp Physiol (2011) 1.01
Experimental models of non-alcoholic fatty liver disease in rats. World J Gastroenterol (2014) 0.96
Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. Amino Acids (2014) 0.93
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A). Bioorg Med Chem (2010) 0.93
Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis. Dig Dis Sci (2007) 0.85
New insight into the biochemical pathology of liver in choline deficiency. Crit Rev Biochem Mol Biol (1995) 0.77